Background

Philip R. Troyk is Executive Director of the Pritzker Institute of Biomedical Science and Engineering at Illinois Institute of Technology (IIT) in Chicago, where he is also a professor of biomedical engineering. He serves as Principal Investigator of the Intracortical Visual Prosthesis (ICVP) project, the multi-institution research consortium developing wireless cortical visual prosthetics for patients with complete blindness.

ICVP project

Under Troyk’s leadership, the ICVP consortium has completed three successful human implantations of its fully wireless intracortical visual prosthesis system. The current implant configuration uses 34 wireless miniaturised stimulators carrying 544 electrodes that sit on the surface of the visual cortex. The third implantation was completed on 7 May 2026 at Rush University Medical Center in Chicago.

The system targets people whose blindness sits anatomically downstream of the retina and optic nerve, where retinal prostheses cannot help, by stimulating the visual cortex directly to deliver patterns of artificial sight. ICVP is the first cortical visual prosthesis to use a group of fully implanted, wireless miniaturised stimulators rather than a single tethered array.

Consortium structure

The ICVP project is a multi-institution NIH BRAIN Initiative-funded programme led by Illinois Institute of Technology with collaborating institutions including Johns Hopkins University’s Wilmer Eye Institute, the University of Chicago, the University of Texas at Dallas, Rush University Medical Center (surgical site), The Chicago Lighthouse (research and training home, Hilton Center for Prosthetic Research), and contract suppliers Microprobes for Life Science and Sigenics. The programme has been funded primarily through NIH BRAIN Initiative grants over nearly three decades.

Strategic position

ICVP is one of four vision restoration platforms in active clinical or regulatory progression in 2026, alongside ReVision Implant’s Occular, Neuralink’s Blindsight, and Science Corporation’s PRIMA. Troyk’s consortium model (NIH-funded, multi-university, building toward regulatory pathway over a long horizon) resembles the early BrainGate consortium model and contrasts with the venture-backed clinical pathway most other brain-implant companies are following.